| William Guyer |
William Guyer is currently the Director-HIV Pharmacy at Kaiser Foundation Health Plan, Inc. and the Chief Development Officer at Corcept Therapeutics, Inc. He previously worked as the Senior VP & Global Head-Medical Affairs at Gilead Sciences, Inc. from 2015 to 2021. Dr. Guyer holds a doctorate degree from the University of Southern California. |
| Joseph Douglas Lyon |
Joseph Douglas Lyon is currently the Chief Technology & Accounting Officer at Corcept Therapeutics, Inc. He previously worked as the Director-Operations Business Development at Connor Group, an Auditor at Ernst & Young, Inc., and as the Worldwide Corporate Controller & General Manager at Zinfi Technologies, Inc. Mr. Lyon obtained his undergraduate degree from the University of Utah. |
| Sean Maduck |
Sean Maduck is currently the Director-San Francisco Bay Area at Cancer Support Community and the President-Corcept Endocrinology at Corcept Therapeutics, Inc. He previously worked as the Director at Wellness Community. Mr. Maduck has an undergraduate degree from Dartmouth College, a graduate degree from Stanford Graduate School of Business, and another undergraduate degree from Thayer School of Engineering At Dartmouth. |
| Amy E. Flood |
Amy E. Flood is currently the Director at Point Source Youth and the Chief Human Resources & Communications Officer at Corcept Therapeutics, Inc. She was previously the Senior Vice President-Public Affairs at Gilead Sciences, Inc. Ms. Flood is a graduate of The Johns Hopkins University. |
| Hazel Hunt |
Hazel Hunt is currently the Chief Scientific Officer at Corcept Therapeutics, Inc. She previously worked as the Operations Director at Pulmagen Therapeutics (Synergy) Ltd. and as the Director-Chemistry & Operations at Argenta Bank en Verzekeringsgroep NV. Hazel also held positions as a Principal at the University of Oxford and the University of California, Davis, as well as a Senior Chemist at Glaxo Group Research Ltd. She completed her undergraduate degree at the Australian National University and obtained a doctorate from the University of Southampton. |
| Atabak Mokari |
Atabak Mokari is currently the Chief Financial Officer & Treasurer at Corcept Therapeutics, Inc. Prior to his current position, he held various roles including Director-Healthcare Investment Banking Group at Wells Fargo Securities LLC from 2013 to 2016, Chief Financial Officer & VP-Corporate Development at IRIDEX Corp. from 2016 to 2018, and Chief Financial Officer at Bellicum Pharmaceuticals, Inc. from 2018 to 2020. He also worked as an Analyst at Olympus Partners LP and Bowles Hollowell Conner & Co. Additionally, he served as an Associate at Credit Suisse Group AG from 2005 to 2009. Mr. Mokari completed his undergraduate degree at Duke University in 1998 and earned an MBA from Tuck School of Business at Dartmouth in 2005. |
| James N. Wilson |
James N. Wilson is currently the Chairman of Corcept Therapeutics, Inc. and a Director at The Palo Alto Medical Foundation. He previously served as Chairman & CEO of Neurex Corp., CEO of Lifescan, Inc., Chairman of Tecan Genomics, Inc., Chairman of Amira Medical, Inc., and Lead Independent Director of Amylin Pharmaceuticals, Inc. He was also President & COO of Syntex Corp. Wilson is a Director at A Stepping Stone Foundation and Insight Prison Project. He holds undergraduate and MBA degrees from the University of Arizona. |
| Joseph K. Belanoff |
Joseph K. Belanoff is the founder. He founded Corcept Therapeutics, Inc. in 1998 and currently holds the title of President, Chief Executive Officer & Director. Dr. Belanoff's former job was as the Psychopharmacology Director-Outpatient Division at Palo Alto Veterans Affairs Hospital from 1997 to 2001. Dr. Belanoff's education includes an undergraduate degree from Amherst College and a doctorate from Columbia University College of Physicians & Surgeons. |
| Monica Tellado |
Monica Tellado is currently the President-Emerging Markets at Corcept Therapeutics, Inc. She previously worked as an Independent Director at DermTech, Inc. from 2021 to 2023, and as the Senior VP-Finance & Investor Relations at Gilead Sciences, Inc. from 2020 to 2022. She also served as the Chief Financial Officer at HeartFlow, Inc. from 2022 to 2023. Ms. Tellado holds an MBA from Carnegie Mellon University and an undergraduate degree from Universidad Pontificia Comillas. |
| Joshua M. Murray |
Joshua M. Murray is an Independent Director at Corcept Therapeutics, Inc. and Senior VP-Finance, Strategy & Investor Relations at Orca Biosystems, Inc. He completed his undergraduate degree at Harvard College. |
| Gillian M. Cannon |
Gillian M. Cannon is currently serving as an Independent Director at Corcept Therapeutics, Inc., Director at Affibody AB, Director at Xenon Pharmaceuticals, Inc., Director at Edinburgh Innovations Ltd., and Head-Commercial Innovation at Roivant Sciences, Inc. She is also the President of Alyvant, Inc. Dr. Cannon has previously worked as the President-North American Operations at UCB, Inc. and Vice President-Commercial Operations at Merck BioVentures. She has an undergraduate degree from The University of Edinburgh and doctorate degrees from Temple University (Pennsylvania) and Fox School of Business. |
| Kimberly Park |
Kimberly Park is currently an Independent Director at Corcept Therapeutics, Inc., a Director at Besser Co., and a Director at Tech-Etch, Inc. She previously worked as the Global VP-Customer Strategy & Innovation at Merck & Co., Inc. from 2014 to 2018, as the Vice President-Managed Care Marketing at Merck & Co., Inc. from 1997 to 2005, as the Vice President-Sales & Marketing at Janssen Pharmaceuticals, Inc. from 2005 to 2010, as the Head-US Global Marketing & Research at GSK Plc from 1985 to 1997, and as the Global VP-Janssen Healthcare Innovation at Johnson & Johnson Services, Inc. from 2010 to 2014. She received her undergraduate degree from the University of Michigan. |
| Gregg Huber Alton |
Gregg Huber Alton is currently serving as an Independent Director at Novavax, Inc., Corcept Therapeutics, Inc., and Renovaro, Inc. He is also the Lead Independent Director at Renovaro, Inc. Additionally, he holds positions as a Director at Boys & Girls Club of Oakland, Gilead Foundation, The Aids Institute, Inc., The Black Women's Health Imperative, Brii Biosciences Ltd., Brii Biosciences Ltd. (China), and Hepatitis Fund. Furthermore, he is a Trustee-Emeritus at Partners In Health. Previously, he served as an Independent Director at Sonoma Pharmaceuticals, Inc. and Celladon Corp. He also held positions at Pharmaceutical Research & Manufacturers of America, The Bay Area Bioscience Association, and Collidion, Inc. (California). Prior to his current and former roles, he worked as the Chief Patient Officer at Gilead Sciences, Inc. and as an Associate Attorney at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC. He started his career as an Attorney at Cooley Godward LLP. Mr. Alton completed his undergraduate studies at the University of California, Berkeley in 1989 and obtained his graduate degree from Stanford Law School in 1993. |
| George Leonard Baker |
George Leonard Baker is currently an Independent Director at Corcept Therapeutics, Inc., a Director at Roplast Industries LLC, an Independent Director at Youku Tudou, Inc., a Partner at Sutter Hill Ventures LLC, a Trustee at Yale University, a Trustee at Environmental Defense Fund, Inc., and a Senior Advisor at Appian Capital Advisory LLP. He has formerly been a Director at Therma-Wave, Inc., Praecis Pharmaceuticals, Inc., Metrika, Inc., InfoMedics, Inc., and Line 6, Inc. He was also an Independent Director at Youku, Inc. from 2007 to 2012. Additionally, he currently holds positions as a Director at Beijing Shiji Yaolan Network Technology Co., Ltd., a Principal at Cummins, Inc., an Investment Committee Member at Yale University Endowment, and an Advisory Board Member at Elm Street Advisors LLC. Mr. Baker holds an MBA from Stanford University and an undergraduate degree from Yale University. |
| Daniel N. Swisher |
Daniel N. Swisher's current job(s) include Chairman at Cerus Corp., Independent Director at Corcept Therapeutics, Inc., and Director at Protagonist Therapeutics, Inc. Mr. Swisher's former job(s) include President, CEO, Secretary & Director at Sunesis Pharmaceuticals, Inc., Senior Vice President-Sales & Marketing at ALZA Corp., President & Chief Operating Officer at Jazz Pharmaceuticals, Inc., and President at Jazz Pharmaceuticals Plc. Mr. Swisher's education history includes an undergraduate degree from Yale University and an MBA from Stanford Graduate School of Business. |
| David L. Mahoney |
David L. Mahoney is currently serving as an Independent Director at Corcept Therapeutics, Inc., Jen Bekman Projects, Inc., Mercy Corps, Mount Holyoke College, Laudus Trust, NCPB, Inc., Schwab Funds, Transformational CPG Acquisition Corp., and as a Trustee at San Francisco Museum of Modern Art. Previously, he held positions as Co-President & Co-Chief Executive Officer at McKesson Corp., Chief Executive Officer at Mckesson Health Solutions LLC and iMcKesson LLC, Non-Executive Chairman at Adamas Pharmaceuticals LLC, Independent Director at Gen Digital Inc., Director at Tercica, Inc., and President-Healthcare Delivery Systems Unit at PCS Health Systems, Inc. He also worked as a Principal at McKinsey & Co., Inc. Mr. Mahoney completed his undergraduate studies at Princeton University and holds an MBA from Harvard Business School. |
